The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 1, 2000, Pages 214-218

  Walsh, Brian W ^a   Paul, Sofia ^b   Wild, Robert A ^c   Dean, Robert A ^b   Tracy, Russell P ^d   Cox, David A ^b   Anderson, Pamela W ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; HOMOCYSTEINE; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; MENOPAUSE; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; RISK FACTORS;

EQUIDAE;

EID: 0034456409     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.1.214     Document Type: Article

References (31)

1. Postmenopausal hormone therapy and mortality
2. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
3. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Fragmin during instability in coronary artery disease
4. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
5. C-reactive protein adds to the predictive value of total, and HDL cholesterol in determining risk of first myocardial infarction
6. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
7. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (AKIC) study
8. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
9. The use of a self-administered questionnaire to assess diet four years in the past
10. Variability in the measurement of Creactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
11. Rapid high performance liquid chromatographic assay for total plasma homocysteine levels in human serum
12. The application of the principle of intentionto-treat to the analysis of clinical trials
13. The jackknife estimate of variance
14. C-Reactive protein: The best laboratory indicator available for monitoring disease activity
15. Hormone replacement therapy, inflammation, and hemostasis in elderly women
16. Oral contraceptive use is associated with systemic acute phase response
17. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
18. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function
19. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more angina but less death/MI during follow-up
20. A randomized controlled study of the effects of 17βestradiol-dydrogesterone on plasma homocysteine in postmenopausal women
21. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels
22. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women
23. Tamoxifen reduces plasma homocysteine levels in healthy women
24. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
25. CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein complexes
26. Processes in atherogenesis: Complement activation
27. C-Reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
28. C-reactive protein increases production of IL-1α, IL-1β, and TNF-α, and expression of mRNA by human alveolar macrophages
29. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
30. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy
31. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins